DMS-44013, Rev. A; Approved 16 Jan, 2025



EverPatch+

Permanent Scleral Reinforcement Matrix

INSTRUCTIONS FOR USE

Device Description

The EverPatch+ is a synthetic permanent tissue-integrating surgical matrix made of nondegradable polymer fibers. The EverPatch+ is provided as a set of two 100 μ m – thick implants with distinct designs to accommodate a range of surgical applications:

- 1. **Rectangular Patch**: Measuring 5.0 mm x 6.5 mm with rounded corners. This patch includes 6 bio-stitching holes located at the periphery, which are designed to anchor the device and support its bio-integration. These holes also guide the physician in suturing the device to the sclera.
- 2. **Shield-Shaped Patch**: Measuring 5.0 mm x 8.5 mm with rounded corners. This patch includes 4 bio-stitching holes which are designed to anchor the device and support its bio-integration. These holes also guide the physician in suturing the device to the sclera. Two integrated loops can be used to help position the device when reinforcing the sclera in the context of glaucoma drainage device implantation.

The physician should select the patch appropriate to the intended surgical site. It is possible to implant both patches in a single procedure, but it is not recommended to overlap them.



Structure, features, and dimensions of the EverPatch+

Indication for Use

The EverPatch+ is intended for implantation to reinforce the sclera and aid the physical reconstruction of the ocular surface.

Contraindication

The EverPatch+ should not be used in surgical sites where active inflammation of any cause is present, or sites with poor perfusion.

Caution

Federal law restricts this device to sale by or on the order of a physician.

Sterilization

The EverPatch+ is sterilized by vaporized hydrogen peroxide. The device is provided in a sterile double blister.

Storage

Store the EverPatch+ in a clean and dry environment at room temperature. Keep away from direct sunlight or extreme temperatures.

Potential Complications

The surgeon should inform the patient of potential complications which may occur following EverPatch+ implantation:

- Patient discomfort from inflammation which can occur due to foreign body reaction.
- Detachment of the device from surrounding tissue in case of trauma or when chronic inflammation is not addressed.
- Conjunctival retraction or wound dehiscence, which may lead to exposure of the device and could require a corrective procedure.

The surgeon should instruct the patient to seek immediate medical attention if any of these complications are observed.

Report any serious incident occurring in relation to the device:

CorNeat Vision complaints:	Food and Drug Administration MedWatch:
complaints@corneat.com	https://www.accessdata.fda.gov/scripts/medwatch/index.cfm
1-507-267-6328	1-800-332-1088

Warnings

Certain conditions may impair healing and reduce the effectiveness of the EverPatch+. These include:

- Scarred or friable conjunctiva.
- Previous Mitomycin C use in the implanted eye.
- Systemic conditions such as uncontrolled diabetes and use of cytotoxic drugs or immunosuppression.
- Uncontrolled ocular surface disease such as severe dry eye or neoplasia.

- History of radiation therapy to the eye region.
- Scleral melt.
- Significant hypotony caused by a leak.

When implanting the EverPatch+ in these patients, precautions should be taken to protect against wound dehiscence.

Precautions

- Prior to use, the surgeon must become familiar with the device and the surgical procedure.
- The device should not be implanted directly under a conjunctival incision.
- The anterior edge of the EverPatch+ should be placed at least 1 mm posterior to the limbus, to reduce the potential risk of conjunctival dehiscence and exposure of the patch.
- When dissecting the conjunctiva ensure complete dissection of Tenon's capsule, to avoid folding of the EverPatch+ onto itself due to remnant bands of Tenon.
- The EverPatch+ should not be left exposed; ensure complete coverage with conjunctiva or other tissue.
- Avoid using cautery in the surgical field, as it may affect tissue perfusion and hinder proper healing.
- Avoid using Mitomycin C directly under the area where the EverPatch+ will be placed.
- Consider using interrupted sutures to close the conjunctival wound until it is fully healed.
- Use the device on a single occasion for a single patient. Once the package is opened, the device must be used for the on-going procedure or discarded.
- Inspect the packaging and labeling. Do not use if the package is opened or damaged. Do not use past the expiration date printed on the label. Do not use if label information is not legible.
- The device's sterile pack is comprised of 2 sealed blisters. Each of the blisters forms a complete sterile barrier. Apply sterile product handling techniques for device preparation prior to implantation.
- An additional EverPatch+ device should be immediately available in case of unexpected need during the procedure.
- Do not re-sterilize.

Instructions for Use

It is important to read and understand the following instructions prior to use. Improper technique may adversely affect the success of the surgical procedure.

EverPatch+ preparation and implantation

- Open the outer blister and place the inner blister on a sterile area.
- Open the inner blister and remove the protective holder.

- Carefully open the protective holder and remove the EverPatch+ using forceps or a similar tool.
- Hydrate the device prior to use by soaking it in a sterile saline solution at room temperature. Antibiotic agents may be added to the soaking saline at surgeon's discretion.
- Ensure there is a sufficient amount of overlying tissue to fully cover the patch, preventing any part of the device from being exposed.
- Closure of the conjunctival wound should not be performed directly above the EverPatch+. Perform the conjunctival incision distant from the surgical field.
- The EverPatch+ is designed to be used as supplied, no trimming is necessary. Use the device as supplied- **do not trim**.
- Suture the device to the sclera through the suturing holes, using minor to moderate tension. Sutures may pass through the matrix if needed.

Follow-up

Periodic follow-up is recommended. In the short term after surgery, more frequent follow-up visits should be conducted to ensure proper wound healing. An ophthalmologist should verify the EverPatch+ integrity and examine the surrounding tissue every 6 months.

Symbol	Title	Description	Standard	Reference Number
REF	Catalogue number	Indicates the manufacturer's catalogue number so that the medical device can be identified	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.1.6
LOT	Batch code	Indicates the manufacturer's batch code so that the batch or lot can be identified	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.1.5
2	Use-by date	Indicates the date after which the medical device is not to be used	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.1.4

Symbols Glossary

Symbol	Title	Description	Standard	Reference Number
	Consult instructions for use or consult electronic instructions for use	Indicates the need for the user to consult the instructions for use	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.4.3
R only	Prescription only	Federal law restricts this device to sale by or on the order of a physician	Guidance for Industry and FDA on Alternative to certain Prescription Device Labeling Requirements	N/A
	Manufacturer	device manufacturer	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.1.1
2	Do not re-use	Indicates a medical device that is intended for one single use only	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.4.2
STERILE VH2O2	Sterilized using vaporized hydrogen peroxide	device that has been	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.2.10
	Do not use if package is damaged and consult instructions for use	Indicates that a medical device that should not be used if the package has been damaged or opened and that the user should consult the instructions for use for additional information	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.2.8
\bigcirc	Double sterile barrier system	Indicates two sterile barrier systems	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.2.12

Symbol	Title	Description	Standard	Reference Number
(2) Series	Do not resterilize	Indicates a medical device that is not to be resterilized	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.2.6
豢	Keep away from sunlight	Indicates a medical device that needs protection from light sources	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.3.2
15 °C	Temperature limit	which the medical	ISO 15223-1 Fourth edition 2021- 07: Medical devices - Symbols to be used with information to be supplied by the manufacturer - Part 1: General requirements	5.3.7
MR		An item that poses no known hazards resulting from exposure to any MR environment. MR Safe items are composed of materials that are electrically nonconductive, nonmetallic, and nonmagnetic.	ASTM F2503 – 20 Standard Practice for Marking Medical Devices and Other Items for Safety in the Magnetic Resonance Environment	7.3.1

Manufacturer

CorNeat Vision, Ltd.

4 Hasheizaf St, Raanana Israel 4366411 E-mail: <u>info@corneat.com</u> Website: <u>www.corneat.com</u>